Industry Newsoncologyras mapkerascaclinical stage
Erasca Advances RAS Therapies Toward Phase 1 Data
4.2
Erasca, Inc. (ERAS), a clinical-stage biotech focused on RAS/MAPK-driven cancers, is advancing its two lead assets—ERAS-0015 and ERAS-4001—into Phase 1 monotherapy trials after IND clearance, with Phase 1 data expected in 2026. The company reported a cash runway into H2 2028 (potentially 2029 after recent offerings) and no revenue, presenting high binary clinical and funding risks.
Key Points
- 1Advances IND-cleared ERAS-0015 and ERAS-4001 into Phase 1 monotherapy trials, data expected 2026
- 2Highlights potential differentiated RAS-targeting potency but faces crowded competition and binary clinical risk
- 3Signals possible high-reward investment if trials succeed, but dilution and funding risks require cautious evaluation
Scoring Rationale
Provides timely company-specific clinical and financial details, limited by single-source bullish thesis and narrow industry scope.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
